How to finance innovative therapies in orphan indications?

German health insurance is facing serious financial challenges. Currently, more than 1 billion additional drug costs are expected, excluding the additional impact new therapies will have.

Against this background, Thomas Wilke is going to present current options and innovative approaches around Pay-for-Performance reimbursement solutions at the upcoming FoGes symposium in Munich on the 24th of October.

Feel free to contact us if you are interested in the presentation.

Contact